The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into peripheral blood during collection for subsequent autologous transplantation in individuals ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...
To undergo kidney dialysis, doctors must first surgically create an access route—an arteriovenous fistula—usually in an arm, ...
WASHINGTON — A procedure that encourages an egg to begin embryo development without being fertilized could suggest a new way to produce stem cells, at least for certain patients. Researchers were able ...
Hematopoietic stem cell (HSC) components may be transplanted between red blood cell antigen-disparate donors and recipients without an increase in graft-versus-host disease (GVHD) or graft rejection.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback